
Leerink analyst Roanna Ruiz lowered the firm’s price target on Kardigan (KARD) to $36 from $37 and keeps an Outperform rating on the shares. The firm views the company’s Q3
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| KARD | Kardigan, Inc. | 12.32 | -8.23 | -40.05% |
| Name | Price | % Change | |
|---|---|---|---|
| $12.32 | -40.05% |

Leerink analyst Roanna Ruiz lowered the firm’s price target on Kardigan (KARD) to $36 from $37 and keeps an Outperform rating on the shares. The firm views the company’s Q3

Cash, cash equivalents and investments were $591.4 million as of September 30, 2026, compared to $335.5 million as of December 31, 2025. The increase primarily reflects net proceeds from the

“We made meaningful progress this quarter in advancing our portfolio of late-stage cardiovascular programs for people who urgently need better treatment options,” said Tassos Gianakakos, co-founder, chief executive officer and

Kardigan, Inc. ( ($KARD) ) just unveiled an announcement. On November 6, 2026, Kardigan completed enrollment in its Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis. It

Kardigan (KARD) announced enrollment completion in the Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis, or AS. The company also shared insights from a pre-planned analysis of

H.C. Wainwright initiated coverage of Kardigan (KARD) with a Buy rating and $42 price target The company has defined large cardiovascular markets with first-to-market potential and three late stage studies

Cantor Fitzgerald initiated coverage of Kardigan (KARD) with an Overweight rating and $50 price target Kardigan is a clinical-stage biotech targeting genetic dilated cardiomyopathy, calcific aortic valve stenosis, and acute

Cantor Fitzgerald initiated coverage of Kardigan (KARD) with an Overweight rating and $50 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

Baird initiated coverage of Kardigan (KARD) with an Outperform rating and $43 price target The firm likes the company’s three asset precision cardiology portfolio. Danicamtiv has the potential to improve

William Blair initiated coverage of Kardigan (KARD) with an Outperform rating. Kardigan is a clinical-stage cardiovascular company that applies precision medicine and AI-enabled cardiac data to develop first-in-class therapies for
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Assigned | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Initiated | Oct 21, 2026 | ||||
| buy | Initiated | Oct 15, 2026 | ||||
| buy | Assigned | Aug 25, 2026 | ||||
| buy | Initiated | Jul 13, 2026 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.